Facetten
Zugriff
Einrichtung
Medientyp
- Text 3
Karte
Erscheinungsjahr
Autor/in
- Dimopoulos, Meletios
- Weisel, Katja 3
- Basu, Supratik 1
- Byeff, Peter 1
- Campioni, Marco 1
- alle zeigen
Sprache
- Englisch 3
3 Einträge gefunden
-
Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma
- Weisel, Katja
- Dimopoulos, Meletios
- Moreau, Philippe
- Yagci, Munci
- Larocca, Alessandra
- Kanate, Abraham S
- Vural, Filiz
-
Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials
- Weisel, Katja
- Majer, Istvan
- DeCosta, Lucy
- Oriol, Albert
- Goldschmidt, Hartmut
- Ludwig, Heinz
- Campioni, Marco
-
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study
- Dimopoulos, Meletios
- Quach, Hang
- Mateos, Maria-Victoria
- Landgren, Ola
- Leleu, Xavier
- Siegel, David
- Weisel, Katja